Literature DB >> 17524597

Appendiceal neoplasms and pseudomyxoma peritonei: a population based study.

R M Smeenk1, M L F van Velthuysen, V J Verwaal, F A N Zoetmulder.   

Abstract

BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare disease with an estimated incidence of 1 per million per year, and is thought to originate usually from an appendiceal mucinous epithelial neoplasm. However it is not known exactly how often these neoplasms lead to PMP. The aim of this study is to investigate the incidence of both lesions and their relation.
METHODS: The nationwide pathology database of the Netherlands (PALGA) was searched for the incidence of all appendectomies, the incidence of primary epithelial appendiceal lesions and the incidence and pathology history of patients with PMP. All regarded the 10-year period of 1995-2005.
RESULTS: In the 10-year period 167,744 appendectomies were performed in the Netherlands. An appendiceal lesion was found in 1482 appendiceal specimens (0.9%). Nine percent of these patients developed PMP. Coincidentally, an additional epithelial colonic neoplasm was found in 13% of patients with an appendiceal epithelial lesion. A mucinous epithelial neoplasm was identified in 0.3% (73% benign, 27% malignant) of appendiceal specimens and 20% of these patients developed PMP. For mucocele and non-mucinous neoplasm the association with PMP was only 2% and 3%, respectively. From the nationwide database 267 patients (62 men and 205 women) with PMP were identified, which demonstrates an incidence of PMP in the Netherlands approaching 2 per million per year. The primary site was identified in 68% and dominated by the appendix (82%).
CONCLUSIONS: Primary epithelial lesions of the appendix are rare. One third of these lesions are mucinous epithelial neoplasms and especially these tumours may progress into PMP. The incidence of PMP seems to be higher than thought before. Furthermore there is a considerable risk of an additional colonic epithelial neoplasm in patients with an epithelial neoplasm at appendectomy.

Entities:  

Mesh:

Year:  2007        PMID: 17524597     DOI: 10.1016/j.ejso.2007.04.002

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  118 in total

1.  Pseudomyxoma peritonei.

Authors:  Katharine E Bevan; Faheez Mohamed; Brendan J Moran
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

2.  Appendiceal mucocele: case reports and review of current literature.

Authors:  Kemal Karakaya; Figen Barut; Ali-Ugur Emre; Hamdi-Bulent Ucan; Guldeniz-Karadeniz Cakmak; Oktay Irkorucu; Oge Tascilar; Yucel Ustundag; Mustafa Comert
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

3.  Risk-reducing laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique.

Authors:  Rebecca Fish; Chelliah Selvasekar; Peter Crichton; Malcolm Wilson; Paul Fulford; Andrew Renehan; Sarah O'Dwyer
Journal:  Surg Endosc       Date:  2013-09-06       Impact factor: 4.584

4.  The importance of gender in patients with peritoneal metastases of appendiceal origin treated by cytoreduction and intraperitoneal chemotherapy: an analysis of 257 consecutive patients from an Australian centre.

Authors:  Lawson Ung; Terence C Chua; David L Morris
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-21       Impact factor: 4.553

5.  Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative.

Authors:  Nick C Levinsky; Mackenzie C Morris; Koffi Wima; Jeffrey J Sussman; Syed A Ahmad; Jordan M Cloyd; Charles Kimbrough; Keith Fournier; Andrew Lee; Sean Dineen; Sophie Dessureault; Jula Veerapong; Joel M Baumgartner; Callisia Clarke; Mohammad Y Zaidi; Charles A Staley; Shishir K Maithel; Jennifer Leiting; Travis Grotz; Laura Lambert; Ryan J Hendrix; Sean Ronnekleiv-Kelly; Courtney Pokrzywa; Mustafa Raoof; Oliver S Eng; Fabian M Johnston; Jonathan Greer; Sameer H Patel
Journal:  J Gastrointest Surg       Date:  2019-08-19       Impact factor: 3.452

6.  FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.

Authors:  Filippo Pietrantonio; Claudia Maggi; Giuseppe Fanetti; Roberto Iacovelli; Maria Di Bartolomeo; Francesca Ricchini; Marcello Deraco; Federica Perrone; Dario Baratti; Shigeki Kusamura; Elena Tamborini; Alessandra Castano; Paola Valentina Consonni; Ilaria Bossi; Cecilia Gavazzi; Massimo Milione; Giuseppe Pelosi; Filippo de Braud
Journal:  Oncologist       Date:  2014-06-20

Review 7.  Adenocarcinoma of the Appendix Presenting as a Palpable Right Thigh Mass.

Authors:  Marci Handler; Neil Anand; Lawrence Wei; Peter Snieckus
Journal:  J Radiol Case Rep       Date:  2017-04-30

8.  Glycomic Profiling Highlights Increased Fucosylation in Pseudomyxoma Peritonei.

Authors:  Lilli Saarinen; Pirjo Nummela; Hannele Leinonen; Annamari Heiskanen; Alexandra Thiel; Caj Haglund; Anna Lepistö; Tero Satomaa; Sampsa Hautaniemi; Ari Ristimäki
Journal:  Mol Cell Proteomics       Date:  2018-08-02       Impact factor: 5.911

9.  Risk of Appendiceal Neoplasm in Periappendicular Abscess in Patients Treated With Interval Appendectomy vs Follow-up With Magnetic Resonance Imaging: 1-Year Outcomes of the Peri-Appendicitis Acuta Randomized Clinical Trial.

Authors:  Jari Mällinen; Tero Rautio; Juha Grönroos; Tuomo Rantanen; Pia Nordström; Heini Savolainen; Pasi Ohtonen; Saija Hurme; Paulina Salminen
Journal:  JAMA Surg       Date:  2019-03-01       Impact factor: 14.766

10.  Pseudomyxoma peritonei diagnosed 19 years after appendicectomy.

Authors:  Paula F Wrafter; Tara Connelly; Jody Sultan Ali Khan; William P Joyce
Journal:  BMJ Case Rep       Date:  2015-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.